Welcome to our dedicated page for Sonnet BioTherapeutics Holdings news (Ticker: $SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet BioTherapeutics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sonnet BioTherapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sonnet BioTherapeutics Holdings's position in the market.
Sonnet BioTherapeutics (NASDAQ: SONN) announced the presentation of its SB221 study at the ASCO 2024 Annual Meeting. The study focuses on SON-1010, a recombinant human Interleukin-12 linked to Sonnet's albumin binding domain, in combination with atezolizumab (Tecentriq®). This Phase 1b/2a trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SON-1010 administered subcutaneously, alone or with a fixed dose of atezolizumab. The poster session is scheduled for June 3, 2024, from 9:00 AM to 12:00 PM CDT in Hall A, as part of the Gynecologic Cancer session. The study targets patients with platinum-resistant ovarian cancer.
Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company, announced on May 22, 2024, that its Board of Directors is exploring strategic alternatives to maximize stockholder value. The company has engaged Chardan Capital Markets as its financial advisor to assist with assessing options such as partnerships, joint ventures, acquisitions, mergers, and other strategic transactions.
There is no set timetable for this review, and no decisions have been made regarding the strategic alternatives. Sonnet emphasizes that there is no guarantee that the evaluation will result in any definitive transactions, changes, or outcomes favorable to the company or its shareholders.
Sonnet BioTherapeutics (NASDAQ:SONN) has announced updated clinical data for its drug candidate SON-1010, used as a monotherapy or in combination with atezolizumab (Tecentriq®). The trials have enrolled a total of 61 subjects with dose escalation continuing in SB101 and SB221 trials. SON-1010 showed no dose-limiting toxicities and revealed a 10-fold extended half-life compared to rhIL-12, prolonging IFNγ responses without cytokine release syndrome. Clinical benefits were observed in 35% of evaluable patients with advanced solid tumors. Both trials reported stable disease in 60% of patients at the first follow-up scan. Sonnet is increasing the target dose of SON-1010 to enhance efficacy.
SON-1010 was also tested in a Phase 1 trial (SB102) in healthy volunteers, showing a consistent safety profile. Sonnet’s Chief Medical Officer, Dr. Richard Kenney, emphasized the clean data generated for pharmacokinetic and pharmacodynamic analyses. The combination of SON-1010 with atezolizumab may benefit from turning 'cold' tumors 'hot,' upregulating PD-L1. The company plans to further test the drug in higher doses later this year and expects more updates early next year.
Sonnet BioTherapeutics (NASDAQ:SONN) reported its FY 2024 Q2 and year-to-date business and earnings update. Key highlights include the publication of Phase 1 data showing the safety and tolerability of SON-1010 in Frontiers in Immunology and early safety data from the Phase 1b/2a trial of SON-080 for CIPN. The company received $4.3 million from New Jersey’s tax program. Financials show $3.8 million in cash and reduced R&D and administrative expenses, reflecting cost-saving measures. New partnerships and further development of SON-080 for diabetic peripheral neuropathy are planned.
Sonnet BioTherapeutics Holdings, a biopharmaceutical company, will participate in the EF Hutton Annual Global Conference on May 15, 2024, in New York. Key executives will present, and investor meetings will be held.